Law360, New York (May 19, 2004, 12:00 AM EDT) -- The European Patent Office has revoked U.S. biotechnology company Myriad Genetics’ European patent on a controversial breast cancer genetic test that critics claim is excessively expensive.
The patent covers a test to predict if a woman is at high risk of developing breast cancer by looking for mutations in a gene called BRCA1.
“After a public hearing of all parties to the opposition proceedings against the patent, the division - a panel composed of three patent examiners and a legal expert - concluded that the grounds...
EPO Revokes Controversial Patent For Breast Cancer Screening
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
